Literature DB >> 33037065

The Amino-Terminal Oligomerization Domain of Angiopoietin-2 Affects Vascular Remodeling, Mammary Gland Tumor Growth, and Lung Metastasis in Mice.

Emmi Kapiainen1,2,3, Minna K Kihlström1,2,3, Riikka Pietilä1,2,3, Mika Kaakinen3, Veli-Pekka Ronkainen3, Hongmin Tu3, Anne Heikkinen1,2,3, Raman Devarajan1,2,3, Ilkka Miinalainen3, Anna Laitakari1,2,3, Mohammadhassan Ansarizadeh1,2,3, Qin Zhang2,3, Gong-Hong Wei2,3, Lloyd Ruddock2,3, Taina Pihlajaniemi1,2,3, Harri Elamaa1,2,3, Lauri Eklund4,2,3.   

Abstract

Angiopoietin-2 (ANGPT2) is a context-dependent TIE2 agonistic or antagonistic ligand that induces diverse responses in cancer. Blocking ANGPT2 provides a promising strategy for inhibiting tumor growth and metastasis, yet variable effects of targeting ANGPT2 have complicated drug development. ANGPT2443 is a naturally occurring, lower oligomeric protein isoform whose expression is increased in cancer. Here, we use a knock-in mouse line (mice expressing Angpt2443), a genetic model for breast cancer and metastasis (MMTV-PyMT), a syngeneic melanoma lung colonization model (B16F10), and orthotopic injection of E0771 breast cancer cells to show that alternative forms increase the diversity of Angpt2 function. In a mouse retina model of angiogenesis, expression of Angpt2443 caused impaired venous development, suggesting enhanced function as a competitive antagonist for Tie2. In mammary gland tumor models, Angpt2443 differentially affected primary tumor growth and vascularization; these varying effects were associated with Angpt2 protein localization in the endothelium or in the stromal extracellular matrix as well as the frequency of Tie2-positive tumor blood vessels. In the presence of metastatic cells, Angpt2443 promoted destabilization of pulmonary vasculature and lung metastasis. In vitro, ANGPT2443 was susceptible to proteolytical cleavage, resulting in a monomeric ligand (ANGPT2DAP) that inhibited ANGPT1- or ANGPT4-induced TIE2 activation but did not bind to alternative ANGPT2 receptor α5β1 integrin. Collectively, these data reveal novel roles for the ANGPT2 N-terminal domain in blood vessel remodeling, tumor growth, metastasis, integrin binding, and proteolytic regulation. SIGNIFICANCE: This study identifies the role of the N-terminal oligomerization domain of angiopoietin-2 in vascular remodeling and lung metastasis and provides new insights into mechanisms underlying the versatile functions of angiopoietin-2 in cancer.See related commentary by Kamiyama and Augustin, p. 35. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33037065     DOI: 10.1158/0008-5472.CAN-19-1904

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Distinct Clinical Impact and Biological Function of Angiopoietin and Angiopoietin-like Proteins in Human Breast Cancer.

Authors:  Hui Yang; Melody Zhang; Xuan-Yu Mao; Hang Chang; Jesus Perez-Losada; Jian-Hua Mao
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

2.  Cooperation of Angiopoietin-2 and Angiopoietin-4 in Schlemm's Canal Maintenance.

Authors:  Emmi Kapiainen; Harri Elamaa; Ilkka Miinalainen; Valerio Izzi; Lauri Eklund
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-10-03       Impact factor: 4.925

Review 3.  Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.

Authors:  Kabir A Khan; Florence Th Wu; William Cruz-Munoz; Robert S Kerbel
Journal:  EMBO Mol Med       Date:  2021-06-14       Impact factor: 12.137

Review 4.  Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders.

Authors:  Racheal Grace Akwii; Constantinos M Mikelis
Journal:  Drugs       Date:  2021-09-29       Impact factor: 9.546

Review 5.  Mechanism of activation and the rewired network: New drug design concepts.

Authors:  Ruth Nussinov; Mingzhen Zhang; Ryan Maloney; Chung-Jung Tsai; Bengi Ruken Yavuz; Nurcan Tuncbag; Hyunbum Jang
Journal:  Med Res Rev       Date:  2021-10-25       Impact factor: 12.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.